ACLF Patients Awaiting Transplant: Options for Bridge Therapy |
Conferences
eMediNexus Coverage from: 
ACLF Patients Awaiting Transplant: Options for Bridge Therapy

0 Read Comments                

Role of bio-artificial devices (MARS group) – a significant improvement in bilirubin, creatinine, and hepatic encephalopathy.The scope of bridge therapy in acute-on-chronic liver failure (ACLF) – when Model of End-stage Liver Disease (MELD) is 30 or higher, an urgent liver transplantation (LT) should be considered where feasible and in cases with no contraindications.If MELD is below 30 on day 3-7 after the therapy, ACLF grading should be assessed. In the case of no ACLF or grade-1 A...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now